Abstract 216P
Background
A previous pan-cancer single-cell study on the tumor microenvironment (TME), particularly tumor-infiltrating lymphocytes (TILs), highlighted both the heterogeneity and dynamics of various T cell subtypes. However, the spatial heterogeneity of TILs in breast cancer has not been extensively studied. We aimed to investigate the spatial heterogeneity of the TME using spatial transcriptomics.
Methods
We retrospectively collected FFPE samples from five breast cancer cases (2 triple-negative breast cancer [TNBC] with high TILs, 2 TNBC with low TILs, 1 hormone receptor-positive[HR+] breast cancer with TIL high TILs) and performed the Visium Spatial Gene Expression method (10x Genomics). Subsequently, using public TILs single-cell data from a pan-cancer study, we predicted and annotated cell types in each Visium spot (single cell deconvolution). We studied the distribution of T cell subtypes across three layers at 3mm intervals from the most peripheral to the central direction of the tumor.
Results
The distribution of 24 CD4+ subtypes and 17 CD8+ subtypes was examined. In all five cases, the CD8.c.12.Tex.CXCL13 subtype showed a statistically significant increase in cell numbers at the tumor center compared to the periphery. The CD4.c20.Treg.TNFRSF9 subtype displayed a similar trend, with higher cell counts in the tumor center and lower counts in the periphery. Conversely, the CD8.c10.Trm.ZNF683 subtype, a key subtype in the previous pan-cancer study, exhibited varying distribution patterns between cases.
Conclusions
TILs in breast cancer consist of diverse subtypes. Numerical heterogeneity was observed among T cell subtypes, along with spatial heterogeneity between the tumor’s central and peripheral regions. Furthermore, heterogeneity was evident between individual tumors. However, some consistent distribution patterns, such as the CD8.c.12.Tex.CXCL13 population, were also observed across cases. Further studies are needed to determine the clinical significance of this spatial heterogeneity.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
165P - TIGIT inhibition in non-small cell lung cancer: Meta-analysis of clinical efficacy and biomarker correlation
Presenter: Hashim Talib Hashim
Session: Poster Display session
168TiP - A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours
Presenter: Giuseppe Curigliano
Session: Poster Display session
169TiP - Colorectal carcinoma: Low dose immunotherapy in upfront metastatic d/MMR patients (CLOUD study)
Presenter: Anant Ramaswamy
Session: Poster Display session
177P - Ubiquitous neoantigens as targets for T cell recognition in a patient with metastatic pancreatic neuroendocrine tumour
Presenter: Jean-Benoit Tanis
Session: Poster Display session
178P - Comprehensive immunophenotype analysis in anti-PD-1 antibody sensitive and resistant syngeneic mouse model unravels perforin-expressing CD4+T cells dominant cytolytic activity
Presenter: Hiroyuki Inoue
Session: Poster Display session
179P - Impact of exercise training on tumour-infiltrating T cells in human prostate cancer
Presenter: Louise Lehrskov
Session: Poster Display session
180P - Chronic circadian disruption promotes melanoma progression by interfering with NK cells
Presenter: Shuwen Xiao
Session: Poster Display session
181P - Intratumoral heterogeneity of immune infiltrate in leiomyosarcomas
Presenter: Iva Benesova
Session: Poster Display session
182P - Innovative nano-immunotherapy for modulating tumor-immune interactions and microbiome in pancreatic cancer
Presenter: Liane Moura
Session: Poster Display session
183P - CAIX negatively modulates inflammatory and anti-tumor immune responses
Presenter: Eliska Svastova
Session: Poster Display session